Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 15/20 | 0.53 |
| ▸ | ITGA4 | P13612 | 12/20 | 0.53 |
| ▸ | ITGB7 | P26010 | 4/20 | 0.53 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.53 |
| ▸ | ITGA5 | P08648 | 3/20 | 0.51 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.50 |
| ▸ | NOS2 | P35228 | 2/20 | 0.49 |
| ▸ | NOS3 | P29474 | 1/20 | 0.49 |
| ▸ | NOS1 | P29475 | 1/20 | 0.49 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1240417 | 1.00 | ITGB1 (0.53) | ITGB1ITGA4ITGB7ITGA2ITGA5 | |
| Hydrochloric Acid SCHEMBL7391192 | 0.99 | ITGB1 (0.52) | ITGB1ITGA4ITGB7ITGA2ITGA5 | |
| SCHEMBL27542813 | 0.93 | ITGB1 (0.60) | ITGB1ITGA4ITGB7ITGA2LNPEP | |
| SCHEMBL6639882 | 0.93 | ITGB1 (0.60) | ITGB1ITGA4ITGB7ITGA2LNPEP | |
| SCHEMBL28742825 | 0.91 | ITGB1 (0.46) | ITGB1ITGA4ITGB7ITGA2ITGA5 | |
| SCHEMBL28742827 | 0.91 | ITGB1 (0.46) | ITGB1ITGA4ITGB7ITGA2ITGA5 | |
| SCHEMBL28032876 | 0.89 | ITGB1 (0.53) | ITGB1ITGA4ITGB7ITGA2ITGA5 | |
| SCHEMBL370312 | 0.89 | ITGB1 (0.53) | ITGB1ITGA4ITGB7ITGA2ITGA5 | |
| SCHEMBL13726463 | 0.89 | ATM (0.59) | ITGB1ITGA4ITGB7ITGA2NOS2 | |
| SCHEMBL3819618 | 0.89 | TSHR (0.57) | ITGB1ITGA4ITGB7ITGA2ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264566-A1 | ANTI-ALPHAVBETA1 INTEGRIN INHIBITORS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-09-15 | — | — | US | disclosed |
| US-20160264566-A1 | ANTI-ALPHAVBETA1 INTEGRIN INHIBITORS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-09-15 | — | — | US | disclosed |
| EP-1595870-B1 | PROCESS FOR PRODUCING PHENYLALANINE DERIVATIVE HAVING QUINAZOLINEDIONE SKELETON AND INTERMEDIATE FOR THE SAME | AJINOMOTO KK (JP) | 2015-09-23 | — | — | EP | disclosed |
| EP-1700850-B1 | Phenylalanine derivative | AJINOMOTO KK (JP) | 2015-07-15 | — | — | EP | disclosed |
| EP-2803667-A1 | Phenylalanine derivatives | AJINOMOTO CO., INC. (JP) | 2014-11-19 | — | — | EP | disclosed |
| US-8546610-B2 | Method for preparing phenylalanine derivatives having quinazoline-dione skeleton and intermediates for use in the preparation of the derivatives | AJINOMOTO CO., INC. (JP) | 2013-10-01 | — | — | US | disclosed |
| US-8546610-B2 | Method for preparing phenylalanine derivatives having quinazoline-dione skeleton and intermediates for use in the preparation of the derivatives | AJINOMOTO CO., INC. (JP) | 2013-10-01 | — | — | US | disclosed |
| US-8546610-B2 | Method for preparing phenylalanine derivatives having quinazoline-dione skeleton and intermediates for use in the preparation of the derivatives | AJINOMOTO CO., INC. (JP) | 2013-10-01 | — | — | US | disclosed |
| EP-2615087-A2 | Phenylalanine derivatives | AJINOMOTO CO., INC. (JP) | 2013-07-17 | — | — | EP | disclosed |
| US-8318975-B2 | Methods for producing phenylalanine derivatives having a quinazolinedione skeleton and intermediates for production thereof | AJINOMOTO CO., INC. (JP) | 2012-11-27 | — | — | US | disclosed |
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| WO-2007141473-A1 | N-(BENZOYL)-O- [2- (PYRIDIN- 2 -YLAMINO) ETHYL] -L-TYROSINE DERIVATIVES AND RELATED COMPOUNDS AS A5B1 ANTAGONISTS FOR THE TREATMENT OF SOLID TUMORS | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
| US-7250516-B2 | Phenylalanine derivatives | AJINOMOTO CO., INC. (JP) | 2007-07-31 | — | — | US | disclosed |
| EP-1700850-A1 | NOVEL PHENYLALANINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2006-09-13 | — | — | EP | disclosed |
| US-20020035127-A1 | Phenylalanine derivatives | CELLTECH THERAPEUTIS, LIMITED | 2002-03-21 | — | — | US | disclosed |
| US-6329372-B1 | HETEROCYCLIC AMIDE COMPOUNDS ARE ABLE TO INHIBIT THE BINDING OF ALPHA4 INTEGRINS TO THEIR LIGANDS AND ARE OF USE IN THE PROPHYLAXIS AND TREATMENT OF IMMUNE OR INFLAMMATORY DISORDERS. | CELLTECH THERAPEUTICS LIMITED (GB) | 2001-12-11 | — | — | US | disclosed |
| EP-1051399-A1 | PHENYLALANINE DERIVATIVES USEFUL AS PHARMACEUTICAL AGENTS | CELLTECH THERAPEUTICS LIMITED (GB) | 2000-11-15 | — | — | EP | disclosed |
| WO-1999037618-A1 | PHENYLALANINE DERIVATIVES USEFUL AS PHARMACEUTICAL AGENTS | CELLTECH THERAPEUTICS LIMITED (GB) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ITGB5, ITGB1, ITGA2B | ITGB1 2/4885ITGA4 27/4885ITGB7 28/4885 |
| US-20020035127-A1 | Phenylalanine derivatives | PAH, VCAM1, IL4I1 | ITGB1 8/4885ITGA4 5/4885ITGB7 25/4885 |
| US-20160264566-A1 | ANTI-ALPHAVBETA1 INTEGRIN INHIBITORS AND METHODS OF USE | ITGB1, ITGA1, ITGAV | ITGB1 1/4885ITGA4 10/4885ITGB7 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.